OWC Pharmaceutical Research Corp (OWCP)

[crazy horse 0]

Jan 18, 2017 article OWCP has 8 Provisional Patents

OWCP has 8 Provisional Patents. These patents all have value. Usually you wouldn’t waste your time patenting something that’s worthless. What kind of value? No idea, obviously.

OWCP had IRB approval and therefore moved forward on a research agreement with the largest hospital in Israel. That tells me their product has obvious indications of being effective.
The “efficacy test” results are due back by end of January of their Psoriasis product. Due to the IRB approval, naturally we’re all expecting good test results.

OWCP’s Psoriasis Cream is expected to ship by Quarter 2 of 2017. AstraZeneca auctioned off their “troubled” Psoriasis product for $445M in 2015. So, OWCP’s presumably superior product should be worth at least $450M, right?

OWCP has NO TOXIC DEBT. That was announced in an 8-K back in October. (This isn’t some OTC Pink Sheet operation.) They have real investors. That same October 8-K talks about a $300,000 non-interest bearing loan. They have royalty-based distribution deals with MedMar and Michepro, because the distributor obviously has confidence too.

OWCP has a promising Multiple Myeloma product. The PR from March 2016 stated, “(OWCP’s) in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.”

OWCP announced in October that they completed the development of a Medical Cannabis Sublingual Tablet — perfect for those who cannot smoke Marijuana, but also a way for prescribing Doctors to ensure accurate and consistent dosages.

http://ownthefloat.com/index.php/2017/01/18/owcp-did-you-miss-the-boat/